Six years' experience with the discontinuation of BCG vaccination. 2. Cost and benefit of mass BCG vaccination
Language English Country Scotland Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
8219182
DOI
10.1016/0962-8479(93)90056-4
PII: 0962-8479(93)90056-4
Knihovny.cz E-resources
- MeSH
- Cost-Benefit Analysis MeSH
- BCG Vaccine adverse effects economics MeSH
- Child MeSH
- Incidence MeSH
- Infant MeSH
- Humans MeSH
- Mycobacterium Infections epidemiology MeSH
- Infant, Newborn MeSH
- Child, Preschool MeSH
- Tuberculosis epidemiology prevention & control MeSH
- Vaccination economics MeSH
- Check Tag
- Child MeSH
- Infant MeSH
- Humans MeSH
- Male MeSH
- Infant, Newborn MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czechoslovakia epidemiology MeSH
- Names of Substances
- BCG Vaccine MeSH
In 1986 the compulsory mass BCG vaccination of infants born in a selected area of the Czech Republic was abolished. The observed annual risk of tuberculous infection in children aged 0-6 years was below 0.1% and the annual risk of tuberculous disease 7/100,000. The increase of tuberculous cases among nonvaccinated children indicated a protective efficacy of BCG vaccine of 80%. A benefit analysis proved that the advantages and disadvantages of BCG vaccination were in balance. The number of nonvaccinated children developing tuberculosis was so small that mass application of BCG has been found to be redundant. The important advantage of not using the vaccination is the maintenance of the epidemiological and diagnostic value of tuberculin tests. The tests in connection with preventive chemotherapy remain an important tool, enabling control of infected individuals.
References provided by Crossref.org
